NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139)

NCT03342053

CompletedPhase 2

Sponsor: Hoffmann-La Roche

Conditions: Huntington's Disease

Interventions: RO7234292 (RG6042)

Countries: Canada, Germany, United Kingdom

This study will test the safety, tolerability, pharmacokinetics and pharmacodynamics of RO7234292 administered intrathecally to adult patients with Huntington's Disease.

Eligibility overview

Sex: ALL

Age: 25 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Key Inclusion Criteria:

* Must have completed dosing in ISIS 443139-CS1

Key Exclusion Criteria:

* Any new condition or worsening of existing condition that could make the patient unsuitable for participation or interfere with the patient participating in and/or completing the study

Locations (9)

Vancouver, British Columbia, Canada
Berlin, Germany
Bochum, Germany
Ulm, Germany
Birmingham, United Kingdom
Cambridge, United Kingdom
Cardiff, United Kingdom
London, United Kingdom
Manchester, United Kingdom